Crucell Terug naar discussie overzicht

Morphosys year 2010 revenues Eur 87 was EUR 81 en verwacht 2011 +meer dan 20%

1. [verwijderd] 21 januari 2011 23:25

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   koers vandaag 4% gezakt, maar was laatste tijd wel erg hard gestegen.
   
   MorphoSys Reports Preliminary, Unaudited Financial Results for 2010 and Provides First Outlook on 2011.January 21, 2011 / 12:22 am, CET
   
   MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today reported preliminary, unaudited financial results for the full-year 2010 according to International Financial Reporting Standards (IFRS). For 2010, MorphoSys expects full year revenues of approximately EUR 87 million (2009: EUR 81.0 million) and an operating profit of approximately EUR 10 million (2009: EUR 11.4 million). The deviation from guidance issued by the Company on December 10, 2010 (revenues of EUR 91-94 million and operating profit of EUR 13-16 million) is related to the final accounting treatment of the recently signed Pfizer deal. This accounting treatment has no impact on the overall economics of the agreement with Pfizer, or on any cash flows arising from the deal.
   
   For 2011, MorphoSys projects full year revenues of at least EUR 105 million and an operating profit of at least EUR 10 million.
   
   "2010 was a stellar year for MorphoSys," commented Dave Lemus, Chief Financial Officer of MorphoSys. "Our growth story is very strong and we expect to see revenue growth in excess of 20% in 2011."
   
   
2. [verwijderd] 24 januari 2011 22:54

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Print .MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance.January 24, 2011 / 7:30 am, CET
   
   CTA Filing in Late December 2010 Represented the Eighth Clinical Milestone Last Year
   
   
   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received a clinical milestone payment from Boehringer Ingelheim in connection with the regulatory filing of a clinical trial application for a phase 1 trial of a HuCAL-derived antibody. The filing took place in late December 2010 making this the eighth clinical milestone met with partners during the year. Financial details are not disclosed.
   
   "In 2010, we saw eight clinical milestones reached with five different partners which surpassed our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks the start of the first clinical program within our partnership with Boehringer Ingelheim."
   
   MorphoSys's clinical pipeline now comprises ten partnered programs in Phase 1 and five in Phase 2 development as well as the Company's proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.